Skip to main content

Advertisement

SpringerLink
Log in

Sarcopenia in Hodgkin’s lymphoma evaluated with 18-FDG PET/CT, focus on age, performance, and treatment

  • Original Article
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

Abstract

Sarcopenia is defined as a progressive and generalized muscle disorder associated with certain physiological and pathological conditions. We aimed to evaluate the prevalence of sarcopenia in patients with HL using 18-fluoro deoxyglucose (FDG) PET/CT, which would provide a data of muscle mass with the CT compartment and also data of muscle metabolism with the 18-FDG compartment of the imaging modality. Fifty-nine patients diagnosed with HL were included in the study. PET/CT images before and after treatment were evaluated with regard to lumbar muscle mass and metabolism. Mean lumbar muscle evaluation with CT before treatment was 92, 40 HU, and after treatment was 89, 41 HU. Mean metabolic tumor volume (MTV) evaluated with FDG PET before treatment was 4, 13 mm3 while after treatment was 4, 10 mm3. The lumbar muscle mass in terms of HU which was evaluated with CT was observed to be decreased after treatment. Likewise, the metabolic evaluation was observed to be also decreased after treatment. Despite the decline in muscle mass after treatment in the whole group, this decline was particularly observed in the better initial performance group. In patients with BMI > 32, there was a significant decline in muscle mass. Abdominal nodal involvement was related with poorer muscle mass and quality. In HL care, particular attention should be given to patients who are younger and with better physical condition in terms of preserving the muscle reserves and preventing sarcopenia.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, Cooper C, Landi F, Rolland Y, Sayer AA, Schneider SM, Sieber CC, Topinkova E, Vandewoude M, Visser M, Zamboni M, Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2, Bautmans I, Baeyens JP, Cesari M, Cherubini A, Kanis J, Maggio M, Martin F, Michel JP, Pitkala K, Reginster JY, Rizzoli R, Sánchez-Rodríguez D, Schols J (2019) Sarcopenia: revised European consensus on definition and diagnosis. Age Aging 48:16–31

    Article  Google Scholar 

  2. Schaap LA, van Schoor NM, Lips P, Visser M (2018) Associations of sarcopenia definitions and their components, with the incidence of recurrent falling and fractures: the longitudinal aging study Amsterdam. J Gerontol A Biol Sci Med Sci 73:1199–1204

    Article  Google Scholar 

  3. McGregor RA, Cameron-Smith D, Poppitt SD (2014) It is not just muscle mass: a review of muscle quality, composition and metabolism during aging as determinants of muscle function and mobility in later life. Longev Healthspan 3(1):9. https://doi.org/10.1186/2046-2395-3-9

  4. Schaap LA, Koster A, Visser M (2013) Adiposity, muscle mass, and muscle strength in relation to functional decline in older persons. Epidemiol Rev 35:51–65

    Article  Google Scholar 

  5. Keng BMH, Gao F, Teo LLY et al (2019) Associations between skeletal muscle and Myokardium in aging: a syndrome of “cardio-sarcopenia”? J Am Geriatr Soc 67(12):2568–2573. https://doi.org/10.1111/jgs.16132

  6. Yin J, Lu X, Qian Z, Xu W, Zhou X (2019) New insights into the pathogenesis and treatment of sarcopenia in chronic heart failure. Thernostics 9(14):4019–4029

    Article  CAS  Google Scholar 

  7. Yang M, Shen Y, Tan L, Li W (2019) Prognostic value of sarcopenia in lung cancer: a systematic review and meta analysis. Chest 156(1):191–111

    Article  Google Scholar 

  8. Gökyer A, Küçükarda A, Köstek O et al (2019) Relation between sarcopenia and dose-limiting toxicity in patients with metastatic colorectal cancer who received regorafenib. Clin Transl Oncol 21(11):1518–1523. https://doi.org/10.1007/s12094-019-02080-4

  9. Hopancı Bıçaklı D, Çehreli R et al (2019) Evaluation of sarcopenia, sarcopenic obesity, and phase angle in geriatric gastrointestinal cancer patients: before and after chemotherapy. Turk J Med Sci 49(2):583–588

    Article  Google Scholar 

  10. Go SII, Park MJ, Song HN (2016) Prognostic impact of sarcopenia in patients with diffuse large B cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisolone. J Cachexia Sarcopenia Muscle 7:567–576

    Article  Google Scholar 

  11. Chu MP, Lieffers J, Ghosh S (2017) Skeletal muscle density is an independent predictor of diffuse large B cell lymphoma outcomes treated with rituximab based chemoimmunotherapy. J Cachexia Sarcopenia Muscle 8:298–304

    Article  Google Scholar 

  12. Lanic H, Kraut-Tauzia J, Modzelewski R (2014) Sarcopenia is an independent prognostic factor in elderly patients with diffuse large B cell lymphoma treated with immunochemotherapy. Leuk Lymphoma 55(4):817–823

    Article  CAS  Google Scholar 

  13. Nakamura N, Hara T, Shibata Y (2015) Sarcopenia is an independent prognostic factor in male patients with diffuse large B cell lymphoma. Ann Hematol 94:20143–22053

    Article  Google Scholar 

  14. Turkish Society of Hematology. Guidelines of the diagnosis and treatment of lymphomas (Version 2018) http://www.thd.org.tr/thdData/Books/83 Accessed September 2019

  15. National Comprehensive Cancer Network. Hodgkin lymphoma (Version 2.2019) https://www.nccn.org/professionals/physician_gls/pdf/hodgkins.pdf Accessed September 2019

  16. Küppers R, Schwering I, Bräuninger A et al (2002) Biology of Hodgkin's lymphoma. Ann Oncol 13(Suppl 1):11

    Article  Google Scholar 

  17. Schmitz R, Stanelle J, Hansmann ML, Küppers R (2009) Pathogenesis of classical and lymphocyte-predominant Hodgkin lymphoma. Annu Rev Pathol 4:151–174

    Article  CAS  Google Scholar 

  18. Liu WR, Shipp MA (2017) Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma. Blood 130:2265–2270

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, Trakya University Faculty of Medicine, Edirne, Turkey

    Volkan Bas, Elif Gulsum Umit, Mehmet Baysal, Sedanur Karaman Gulsaran, Ufuk Demirci, Hakki Onur Kirkizlar & Ahmet Muzafer Demir

  2. Department of Nuclear Medicine, Trakya University Faculty of Medicine, Edirne, Turkey

    Ulku Korkmaz & Gulay Durmus Altun

Authors
  1. Volkan Bas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elif Gulsum Umit
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ulku Korkmaz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mehmet Baysal
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sedanur Karaman Gulsaran
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ufuk Demirci
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hakki Onur Kirkizlar
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Gulay Durmus Altun
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Ahmet Muzafer Demir
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Elif Gulsum Umit.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This study has been approved by the local ethical committee with the number 2019/322, compliant with 1964 Helsinki declaration.

Informed consent

Written informed consent has been obtained from all living patients.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bas, V., Umit, E.G., Korkmaz, U. et al. Sarcopenia in Hodgkin’s lymphoma evaluated with 18-FDG PET/CT, focus on age, performance, and treatment. Support Care Cancer 29, 2475–2480 (2021). https://doi.org/10.1007/s00520-020-05772-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00520-020-05772-8

Keywords

Search

Navigation